drugset
drugset / Trial / NCT05473533

Study of Single and Multiple Doses of PRS-220 Administered by Oral Inhalation in Healthy Subjects

NCT05473533 ↗

Phase 1 Completed 64 enrolled Pieris Australia Pty Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

A dose escalating study of PRS-220 administered by oral inhalation in healthy subjects

Timeline

Start
2022-10-31
Primary completion
2023-08-11
Completion
2023-08-11

Drugs

EvaluationDrugModalityDoseRoute
Subject PRS-220 Unknown — Inhaled

Indications

No indication recorded.